NEW YORK – Gilead Sciences announced this week that it has closed a previously announced deal with Arcellx to codevelop and co-commercialize that firm's investigational cell therapy, CART-ddBCMA, for patients with relapsed or refractory multiple myeloma. The treatment is currently being evaluated in a Phase II trial. Under the terms of the agreement, Gilead subsidiary Kite Pharma will jointly commercialize the therapy with Arcellx in the US, whereas Kite will exclusively commercialize CART-ddBCMA in ex-US regions.
The White House this week marked the first anniversary of the relaunch of the federal Cancer Moonshot initiative by highlighting efforts that the "reignited" program has supported, including a partnership between the American Society of Clinical Oncology's CancerLinQ and bioinformatics firm Owkin to improve outcomes in metastatic non-small cell lung cancer. The CancerLinQ-Owkin data-sharing collaboration, which started in July, is using artificial intelligence to analyze de-identified real-world clinical and molecular data to identify biomarkers for patients who may be resistant to first-line immunotherapies.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.